Equities

Bioretec Oy

Bioretec Oy

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.91
  • Today's Change-0.07 / -3.54%
  • Shares traded10.82k
  • 1 Year change-17.67%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold0
Sell1
Strong Sell0

Share price forecast in EUR

The one analyst offering a 12 month price target expects Bioretec Oy share price to rise to 2.60 in the next year from the last price of 1.91.
High36.1%2.60
Med36.1%2.60
Low36.1%2.60

Earnings history & estimates in EUR

On Aug 15, 2024, Bioretec Oy reported 2nd quarter 2024 losses of -0.04 per share.
Average growth rate+20.00%
Bioretec Oy reported annual 2023 losses of -0.19 per share on Feb 16, 2024.
Average growth rate-58.33%
More ▼

Revenue history & estimates in EUR

Bioretec Oy had 2nd quarter 2024 revenues of 1.38m. This bettered the 1.11m consensus of the 2 analysts covering the company. The same period last year the company did not report revenues.
Average growth rate+102.20%
Bioretec Oy had revenues for the full year 2023 of 3.91m. This was 32.77% above the prior year's results.
Average growth rate+32.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.